Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03138421
Other study ID # ABX-1431_PN009
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 1, 2017
Est. completion date July 24, 2018

Study information

Verified date January 2019
Source Abide Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.

During the course of this study, each participant will take a daily dose of 20 mg of ABX-1431 or a matching placebo for approximately 7 to 9 weeks.


Description:

This is a double-blind, placebo-controlled crossover study, randomized, crossover study of ABX-1431 HCl as add-on therapy in the treatment of central neuropathic pain.The efficacy of ABX-1431 will also be assessed by the change in pain intensity scores using a numerical rating scale (NRS-11).

All patients will undergo a screening visit for enrollment criteria. Eligible patients will be treated with daily medication for 7 to 9 weeks, which will include some treatment with placebo and some treatment with ABX-1431 HCl. Patients will use a web based application to record their daily average pain using a numerical rating scale (NRS-11).

This study will enroll up to 32 patients with chronic central pain due to one of the four following diagnostic groups: Neuromyeliltis Optica Spectrum Disorder (NMOSD), longitudinally extensive transverse myelitis (LETM), Multiple Sclerosis (MS), and Transverse Myelitis (TM).


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date July 24, 2018
Est. primary completion date July 23, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with chronic central pain, present for at least 3 months due to one of the four following diagnostic groups: NMOSD, LETM, MS, or TM.

- Patient has a diagnosis of NMOSD with anti-AQP4 IgG or without AQP4-IgG as defined by the International Panel for NMO Diagnosis at least 3 months prior to the screening visit (IPND 2015)

- Patients with idiopathic, LETM, comprising an intramedullary MRI lesion or continuous segments of spinal cord atrophy with a clinical history consistent with acute myelitis, and with chronic pain syndrome consistent with the lesion neuroanatomy may be enrolled. These LETM patients must also demonstrate evidence of acute, inflammatory myelopathy in the past (e.g. clinically acute symptomatic myelitis plus inflammatory CSF analysis (e.g. elevated WBC and IgG index) or imaging consistent with inflammatory myelopathy). LETM must be diagnosed at least 3 months prior to the screening visit.

- Patient with MS defined by McDonald criteria [1] or Poser criteria [2] at least 3 months prior to screening visit.

- Patients with post-infectious, autoimmune or idiopathic TM diagnosed by a neurologist at least 6 months prior to the screening visit.

- Patient's chronic pain must be neuropathic in nature, and anatomically plausible based on underlying neuropathology. If patient has an additional source of pain (e.g., vascular ischemic pain, transient spasm associated pain, headache, chronic lower back pain or concomitant osteoarthritic joint pain), the central neuropathic pain must be clearly identifiable by the patient, as assessed by the Investigator.

- The Investigator determines that the patient can enter daily NRS-11 pain intensity data on an internet connected device such as a smart phone, tablet computer or desktop computer with reliable internet service. Patients that do not have a device will be supplied one for the duration of the study. At the direction of the patient, the patient's caregivers may enter the pain intensity data.

- At Visit 2, patient's pain is = 4 on the NRS-11 pain intensity scale, on at least 4 of the 7 days preceding randomization.

- Patients taking immunosuppressive therapy (IST) for relapse prevention of NMOSD or TM or taking disease modifying therapy (DMT) for MS must be on a stable maintenance dose(s) of IST or DMT for 30 days prior to screening and must be expected to maintain the IST or DMT regimenduring this study.

- Patients taking oral corticosteroids must be on a stable dose of medication for at least one week before study start and must be expected to remain on a stable dose during this study. The dose may be no more than prednisolone 20 mg daily or equivalent.

- For patients taking antibody therapy for NMOSD relapse prevention (e.g. rituximab, eculizumab or tocilizumab), therapy must be discontinued at least 6 months prior to screening and patients must be willing to refrain from use during this study.

- Patients taking daily neuropathic or central pain medications (e.g. gabapentin, amitriptyline, lamotrigine) must be on a stable dose of medication for 30 days before study start and must be expected to remain on a stable dose during this study.

- Patients must give written informed consent.

- Patients must be willing and able to comply with the protocol requirements for the duration of the study.

- Female patients of child-bearing potential must have a negative pregnancy test [serum human chorionic gonadotropin (HCG)]. They must practice a highly effective, reliable and medically approved contraceptive regimen during the study (i.e. theoretical failure rate less than 1% per year including oral or parenteral hormonal contraception, Nuvaring, intrauterine device (IUD) or male condom plus spermicide). Post-menopausal women may enter this study. Post-menopausal women are defined as those without menses in the past 12 months, and with a serum follicle stimulating hormone (FSH) in the post-menopausal range. Women who are surgically sterile may enter this study with historical documentation of surgical procedure and a negative pregnancy test.

- Male patients must be willing to use a condom with sexual partners during this study until the poststudy visit. Male patients must be willing to abstain from sperm donation for 3 months after the completion of this study.

Exclusion Criteria:

- Patients with chronic central pain due to trauma, vascular causes, active infection, neoplasm, radiation, metabolic, toxic or other non-inflammatory brain disease or myelopathy are excluded. Patients with trigeminal neuralgia, either as an isolated condition or with MS are excluded. Patients with a history of encephalitis are excluded. Patients with systemic inflammatory autoimmune disorders associated with TM are excluded (e.g. sarcoidosis, systemic lupus erythematosus, Sjogren's syndrome, Behcet's Syndrome, rheumatoid arthritis). TM secondary to infection of the nervous system is excluded (e.g. herpes virus, Lyme disease). TM associated with HIV infection is excluded.

- Patient has an onset of an MS, LETM or TM relapse or NMOSD acute episode within 60 days before the study start.

- Patients with unresolved infections, AIDS myelopathy, or degenerative neurological conditions.

- Patient has received the following within 60 days before study start:

- Intrathecal baclofen.

- Injection therapies such a botulinum toxin, anesthetic or nerve block to control pain.

- Plasma exchange

- Patients taking daily oral opioid drugs are excluded.

- Patient is taking carbamazepine or oxcarbazine or eslicarbazepine or other potent cytochrome P450 3A4/5 inducers [e.g. rifampin, St. John's Wort (Hypericum perforatum), phenytoin]. Patient is taking strong P450 3A4/5 inhibitors including atazanavir, bocepravir, clarithromycin, grapefruit juice, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, or voriconazole.

- Patient has evidence of alcohol, drug or chemical abuse, at study start or within 1 year before the study start.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ABX-1431 HCl
ABX-1431 HCl, capsules, 20 mg
Placebo
Matching placebo

Locations

Country Name City State
United Kingdom The Walton Centre Liverpool
United Kingdom Oxford University Hospitals NHS Foundation Trust Oxford

Sponsors (1)

Lead Sponsor Collaborator
Abide Therapeutics

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in mean pain score between ABX-1431 HCl and placebo based on the Pain NRS-11 ordinal numeric rating scale The treatment difference of ABX-1431 HCl versus placebo is estimated from the change from baseline in daily NRS-11 Pain to the final 7 days of treatment in each two-week treatment period. Baseline levels of pain or taken from the final 7 days of treatment in the period preceding each double-blind treatment period. placebo, treatment (14 days)
Secondary Short Form Brief Pain Inventory (SF-BPI) Scores Difference in the change from baseline between ABX-1431 HCl and placebo placebo, treatment (14 days)
Secondary Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) Difference in the change from baseline between ABX-1431 HCl and placebo placebo, treatment (14 days)
Secondary Patient Global Impression of Change (PGIC) score Difference in the change from baseline between ABX-1431 HCl and placebo placebo, treatment (14 days)
Secondary Proportion of patients achieving and maintaining >30%, >50%, reduction in mean pain intensity score compared to baseline and cumulative proportion of responders' analysis Difference in the change from baseline between ABX-1431 HCl and placebo placebo, treatment (14 days)
Secondary Actigraphically estimated parameters of sleep (WASO, TST, sleep efficiency, average overnight activity counts) and general activity measured by percentage of sedentary time, and moderate to high intensity activity Difference in the change from baseline between ABX-1431 HCl and placebo placebo, treatment (14 days)
Secondary Sleep interference (NRS-11) A NRS-11 scale recording sleep interference due to transverse myelitis pain / central pain in the previous week (in which 0 = no interference and 10 = greatest possible interference) Difference in the change from baseline between ABX-1431 HCl and placebo placebo, treatment (14 days)
Secondary ABX-11431 and metabolite M55 plasma PK Difference in the change from baseline between ABX-1431 HCl and placebo placebo, treatment (14 days)
Secondary 2-AG hydrolysis in PBMC Difference in the change from baseline between ABX-1431 HCl and placebo placebo, treatment (14 days)
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis